scPharmaceuticals Inc. — Director's Dealing 2025

Oct 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: scPharmaceuticals Inc. (SCPH)
CIK: 0001604950
Period of Report: 2025-10-07

Reporting Person: SCHAEFFER LEONARD D (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-10-07	Common Stock	U	68796	—	Disposed	0	Direct
2025-10-07	Common Stock	U	43104	—	Disposed	0	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-10-07	Stock Option (Right to Buy)	$3.85	D	30000	Disposed	2035-06-03	Common Stock (30000)	Direct
2025-10-07	Stock Option (Right to Buy)	$4.11	D	19750	Disposed	2034-06-11	Common Stock (19750)	Direct
2025-10-07	Stock Option (Right to Buy)	$4.53	D	16300	Disposed	2032-06-14	Common Stock (16300)	Direct

Footnotes

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash,

F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.